{
  "paper_id": "d1c0a1bfbc2785ecfaac415612d354f2ffc3bfc5",
  "metadata": {
    "title": "Meplazumab treats COVID-19 pneumonia: an open-labelled, concurrent controlled add-on clinical trial",
    "coda_data_split": "dev",
    "coda_paper_id": 1380,
    "coda_has_expert_labels": false,
    "subset": "biorxiv_medrxiv"
  },
  "abstract": [
    {
      "original_text": "medRxiv preprint Interpretation Meplazumab efficiently improved the recovery of patients with SARS-CoV-2 pneumonia with a favorable safety profile. Our results support to carry out a large-scale investigation of meplazumab as a treatment for COVID-19 pneumonia.",
      "sentences": [
        [
          {
            "segment_text": "medRxiv preprint Interpretation Meplazumab efficiently improved the recovery of patients with SARS-CoV-2 pneumonia with a favorable safety profile .",
            "crowd_label": "background"
          }
        ],
        [
          {
            "segment_text": "Our results support to carry out a large-scale investigation of meplazumab as a treatment for COVID-19 pneumonia .",
            "crowd_label": "finding"
          }
        ]
      ]
    }
  ],
  "abstract_stats": {
    "paragraph_num": "1",
    "sentence_num": "2",
    "segment_num": "2",
    "token_num": "37"
  }
}